RETHYMIC

Sumitomo Pharma America, Inc.🇺🇸 United States

FDA Page

Effective Date: Nov 29, 2023
Approval ID: e0022c28-8cda-4f1e-bcf1-1f440d37ec4a
Products: 1 registered
Version: 6

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use RETHYMIC safely and effectively. See full prescribing information for RETHYMIC. RETHYMIC (Allogeneic processed thymus tissue–agdc) For surgical implantation Initial U.S. Approval: 2021

Quick Stats

Total Products1

Labelers2

Label Sections17

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.